InflaRx N.V (IF0) - Total Liabilities
Based on the latest financial reports, InflaRx N.V (IF0) has total liabilities worth €19.79 Million EUR (≈ $23.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore InflaRx N.V operating cash flow efficiency to assess how effectively this company generates cash.
InflaRx N.V - Total Liabilities Trend (2016–2024)
This chart illustrates how InflaRx N.V's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of InflaRx N.V to evaluate the company's liquid asset resilience ratio.
InflaRx N.V Competitors by Total Liabilities
The table below lists competitors of InflaRx N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
China | CN¥61.89 Million |
|
Heerim Architects & Planners Co. Ltd
KQ:037440
|
Korea | ₩116.90 Billion |
|
Metalstech Ltd
AU:MTC
|
Australia | AU$2.86 Million |
|
Deswell Industries Inc
NASDAQ:DSWL
|
USA | $20.17 Million |
|
Nam Liong Global Corp
TWO:5450
|
Taiwan | NT$1.72 Billion |
|
FingerMotion Inc
NASDAQ:FNGR
|
USA | $43.71 Million |
|
Chin Yang Ind
KO:003780
|
Korea | ₩28.66 Billion |
|
TronicS Microsystems SA
PA:ALTRO
|
France | €17.73 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down InflaRx N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see InflaRx N.V (IF0) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InflaRx N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InflaRx N.V (2016–2024)
The table below shows the annual total liabilities of InflaRx N.V from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €14.60 Million ≈ $17.07 Million |
-17.16% |
| 2023-12-31 | €17.63 Million ≈ $20.61 Million |
+25.46% |
| 2022-12-31 | €14.05 Million ≈ $16.43 Million |
-29.25% |
| 2021-12-31 | €19.86 Million ≈ $23.22 Million |
+91.83% |
| 2020-12-31 | €10.35 Million ≈ $12.10 Million |
-28.26% |
| 2019-12-31 | €14.43 Million ≈ $16.87 Million |
+84.45% |
| 2018-12-31 | €7.82 Million ≈ $9.15 Million |
+63.52% |
| 2017-12-31 | €4.78 Million ≈ $5.59 Million |
-91.33% |
| 2016-12-31 | €55.21 Million ≈ $64.54 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal … Read more